Article Body
Jagsonpal Pharmaceuticals shares surged more than 12% in early trade on Tuesday after the company announced the acquisition of an 85% equity stake in Mumbai-based Aequitas Healthcare Private Limited for ₹20.8 crore. The strategic acquisition marks Jagsonpal's entry into India's fast-growing hospital pharmaceutical segment.
According to the company's announcement, the acquisition will be funded through internal accruals. The existing directors of Aequitas will retain a 15% stake and continue to manage the business, ensuring operational continuity.
Founded in 2017, Aequitas Healthcare focuses on the sale and distribution of pharmaceutical products to hospitals and has built a strong presence across leading hospital chains in India. The company reported revenue of ₹53 crore in FY26.
Jagsonpal said the acquisition aligns with its long-term strategy of expanding its footprint across India's healthcare ecosystem. The hospital segment currently contributes around 10% of the Indian pharmaceutical industry's sales and is growing at a faster pace than other segments.
Commenting on the development, Jagsonpal Pharmaceuticals Managing Director Manish Gupta said the acquisition provides the company with a ready platform to establish a meaningful presence in the hospital business. He added that Jagsonpal's portfolio of established brands is expected to benefit from Aequitas' strong institutional relationships, creating sustainable long-term value for shareholders.
The announcement was well received by investors, with Jagsonpal Pharmaceuticals shares climbing over 12% as the market welcomed the company's strategic expansion into the institutional healthcare market.
Comments